NEW YORK--(BUSINESS WIRE)--Rarecells®, the global leader in cancer’s early diagnosis using circulating tumor cells (CTCs) as advanced indicators of malignancies years before obvious symptoms and signs first appear, is proud to announce the publication of the first study to demonstrate that the ISET by Rarecells® test can allow the diagnosis of lung cancer among Chronic Obstructive Pulmonary Disease (COPD) patients. The independent study, “Sentinel Circulating Tumor Cells Allow early Diagnosis of Lung Cancer in Patients with Chronic Obstructive Pulmonary Disease” was just published in the Public Library of Science (PLOS) ONE open-access journal. The early diagnosis of cancer cells through the ISET®, a simple blood test, holds great promise for improved survivability of lung cancer, a form of cancer where patients are often asymptomatic until the disease is very advanced. Only 15% of lung cancer cases are found in the early stages, before the cancer has spread.i
Help employers find you! Check out all the jobs and post your resume.
